Matches in SemOpenAlex for { <https://semopenalex.org/work/W3037378367> ?p ?o ?g. }
- W3037378367 abstract "Anaplastic Large Cell Lymphoma (ALCL) is a T-cell malignancy predominantly driven by a hyperactive Anaplastic Lymphoma Kinase (ALK) fusion protein. ALK inhibitors such as crizotinib provide alternatives to standard chemotherapy with reduced toxicity and side effects. Children with lymphomas driven by NPM1-ALK fusion proteins achieved an objective response rate to ALK inhibition therapy of 54-90% in clinical trials. However, a subset of patients progress within the first 3 months of treatment. The mechanism for the development of ALK inhibitor resistance is unknown. Through genome-wide CRISPR activation and knockout screens in ALCL cell lines combined with RNA-seq data derived from ALK inhibitor relapsed patient tumors, we show that resistance to ALK inhibition by crizotinib in ALCL can be driven by aberrant upregulation of IL10RA. Elevated IL10RA expression rewires the STAT3 signaling pathway bypassing otherwise critical phosphorylation by NPM1-ALK. IL10RA expression does not correlate with response to standard chemotherapy in pediatric patients suggesting that combination of crizotinib with chemotherapy could prevent ALK-inhibitor resistance-specific relapse. Trials registered as NCT01979536/NCT02034981/UMIN000028075." @default.
- W3037378367 created "2020-07-02" @default.
- W3037378367 creator A5000128919 @default.
- W3037378367 creator A5002010740 @default.
- W3037378367 creator A5007094258 @default.
- W3037378367 creator A5007763268 @default.
- W3037378367 creator A5009137383 @default.
- W3037378367 creator A5010319855 @default.
- W3037378367 creator A5010540932 @default.
- W3037378367 creator A5012101254 @default.
- W3037378367 creator A5015195367 @default.
- W3037378367 creator A5015873287 @default.
- W3037378367 creator A5016825258 @default.
- W3037378367 creator A5019939654 @default.
- W3037378367 creator A5022156956 @default.
- W3037378367 creator A5023327756 @default.
- W3037378367 creator A5023429659 @default.
- W3037378367 creator A5029465890 @default.
- W3037378367 creator A5029547694 @default.
- W3037378367 creator A5036874214 @default.
- W3037378367 creator A5037094473 @default.
- W3037378367 creator A5038786839 @default.
- W3037378367 creator A5042346885 @default.
- W3037378367 creator A5044549759 @default.
- W3037378367 creator A5048087410 @default.
- W3037378367 creator A5050048181 @default.
- W3037378367 creator A5051922909 @default.
- W3037378367 creator A5052133938 @default.
- W3037378367 creator A5056018797 @default.
- W3037378367 creator A5061095336 @default.
- W3037378367 creator A5064969274 @default.
- W3037378367 creator A5067202962 @default.
- W3037378367 creator A5071015212 @default.
- W3037378367 creator A5071036420 @default.
- W3037378367 creator A5072347237 @default.
- W3037378367 creator A5073782592 @default.
- W3037378367 creator A5081788762 @default.
- W3037378367 creator A5085517110 @default.
- W3037378367 creator A5087623080 @default.
- W3037378367 creator A5087860986 @default.
- W3037378367 creator A5089205761 @default.
- W3037378367 date "2020-06-23" @default.
- W3037378367 modified "2023-10-18" @default.
- W3037378367 title "IL10RA Modulates Crizotinib Sensitivity in NPM1-ALK-positive Anaplastic Large Cell Lymphoma" @default.
- W3037378367 cites W1487337897 @default.
- W3037378367 cites W1488829751 @default.
- W3037378367 cites W1549526024 @default.
- W3037378367 cites W1672417844 @default.
- W3037378367 cites W1842992197 @default.
- W3037378367 cites W1923876837 @default.
- W3037378367 cites W1949104778 @default.
- W3037378367 cites W1965807814 @default.
- W3037378367 cites W1968989618 @default.
- W3037378367 cites W1973603971 @default.
- W3037378367 cites W1988349686 @default.
- W3037378367 cites W1990152951 @default.
- W3037378367 cites W1990487163 @default.
- W3037378367 cites W1993428519 @default.
- W3037378367 cites W2003405789 @default.
- W3037378367 cites W2003429746 @default.
- W3037378367 cites W2004899483 @default.
- W3037378367 cites W2007739717 @default.
- W3037378367 cites W2011937137 @default.
- W3037378367 cites W2016783244 @default.
- W3037378367 cites W2019103098 @default.
- W3037378367 cites W2019108602 @default.
- W3037378367 cites W2020182512 @default.
- W3037378367 cites W2031211461 @default.
- W3037378367 cites W2033820733 @default.
- W3037378367 cites W2038586807 @default.
- W3037378367 cites W2041652923 @default.
- W3037378367 cites W2042386826 @default.
- W3037378367 cites W2046455004 @default.
- W3037378367 cites W2051613731 @default.
- W3037378367 cites W2072900107 @default.
- W3037378367 cites W2079116568 @default.
- W3037378367 cites W2080140928 @default.
- W3037378367 cites W2092048234 @default.
- W3037378367 cites W2100122648 @default.
- W3037378367 cites W2103980474 @default.
- W3037378367 cites W2106196606 @default.
- W3037378367 cites W2109078648 @default.
- W3037378367 cites W2124478432 @default.
- W3037378367 cites W2127862779 @default.
- W3037378367 cites W2139526378 @default.
- W3037378367 cites W2144566097 @default.
- W3037378367 cites W2145708480 @default.
- W3037378367 cites W2147038864 @default.
- W3037378367 cites W2151675157 @default.
- W3037378367 cites W2158706332 @default.
- W3037378367 cites W2160516333 @default.
- W3037378367 cites W2161074777 @default.
- W3037378367 cites W2162244898 @default.
- W3037378367 cites W2165014363 @default.
- W3037378367 cites W2170144893 @default.
- W3037378367 cites W2202341402 @default.
- W3037378367 cites W2203210702 @default.
- W3037378367 cites W2230354098 @default.
- W3037378367 cites W2251438188 @default.
- W3037378367 cites W2281569131 @default.